You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Versant Venture Capital IV | 2,736,032 | 0 | 2,736,032 | 0 | 2,736,032 | 6.74% |
| Versant Side Fund IV | 16,224 | 0 | 16,224 | 0 | 16,224 | 0.04% |
| Versant Ventures IV | 0 | 2,752,256 | 0 | 2,752,256 | 2,752,256 | 6.78% |
| Versant Venture Capital V | 1,629,204 | 0 | 1,629,204 | 0 | 1,629,204 | 4.01% |
| Versant Affiliates Fund V | 47,801 | 0 | 47,801 | 0 | 47,801 | 0.12% |
| Versant Ophthalmic Affiliates Fund I | 52,987 | 0 | 52,987 | 0 | 52,987 | 0.13% |
| Versant Ventures V | 0 | 1,729,992 | 0 | 1,729,992 | 1,729,992 | 4.26% |
| Versant Venture Capital V (Canada) | 123,994 | 0 | 123,994 | 0 | 123,994 | 0.31% |
| Versant Ventures V GP-GP (Canada), Inc | 0 | 123,994 | 0 | 123,994 | 123,994 | 0.31% |
| Versant Ventures V (Canada) | 0 | 123,994 | 0 | 123,994 | 123,994 | 0.31% |
Page 1 of 18 – SEC Filing
|
| UNITED STATES |
|
|
| SECURITIES AND EXCHANGE COMMISSION |
|
|
| Washington, D.C. 20549 |
|
|
|
|
|
|
| SCHEDULE 13D |
|
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT
TO RULE 13d-2(a)
(Amendment No. 1)*
CRISPR THERAPEUTICS AG
(Name of Issuer)
Common Stock, par value CHF 0.03 per share
(Title of Class of Securities)
H17182108
(CUSIP Number)
Versant Ventures IV, LLC
Robin L. Praeger
One Sansome Street, Suite 3630
San Francisco, CA 94104
415-801-8100
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
September 5, 2017
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
